Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion in cash, buying the company’s marketed pediatric glioma therapy Ojemda (tovorafenib) and its development-stage oncology programs. The deal, announced March 6, offers Servier an immediate commercial foothold in rare pediatric brain tumors while augmenting its early- to late-stage oncology pipeline. Day One generated about $155 million in sales from Ojemda in 2025 and will be integrated into Servier’s rare‑cancer strategy. Servier said it will fund the purchase with a mix of cash and investments; the transaction carries an approximate 68% premium to Day One’s closing share price and is expected to close in Q2. Company statements highlight product synergies between Ojemda and Servier’s approved Voranigo, while analysts flagged potential upside from Day One’s ADC programs. The acquisition underscores continued buyer appetite for commercial-stage rare oncology assets that add near-term revenue and targeted R&D programs.